RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+5.38%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.43B
AUM Growth
+$1.43B
(+17%)
Cap. Flow
+$174M
Cap. Flow
% of AUM
12.16%
Top 10 Holdings %
Top 10 Hldgs %
28.58%
Holding
96
New
13
Increased
36
Reduced
31
Closed
4
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$34.5M |
| 2 |
Cencora
COR
|
$19.8M |
| 3 |
McKesson
MCK
|
$17.2M |
| 4 |
Intuitive Surgical
ISRG
|
$16.3M |
| 5 |
Abbott
ABT
|
$15M |
Top Sells
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$24.9M |
| 2 |
AbbVie
ABBV
|
$14.3M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$12.2M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$9.46M |
| 5 |
Glaukos
GKOS
|
$7.55M |
Sector Composition
| 1 | Healthcare | 96.33% |
| 2 | Industrials | 0.98% |
| 3 | Technology | 0.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $54.8M | 3.82% | 595,000 -5,000 | -0.8% | -$460K |
|
|
2
Johnson & Johnson
JNJ
$427B
| $53.4M | 3.72% | 325,000 +210,000 | +183% | +$34.5M |
|
3
UnitedHealth
UNH
$281B
| $42M | 2.93% | 113,000 +8,000 | +8% | +$2.98M |
|
4
Jazz Pharmaceuticals
JAZZ
$7.75B
| $41.1M | 2.87% | 250,000 +30,000 | +14% | +$4.93M |
|
|
5
AbbVie
ABBV
$372B
| $39.8M | 2.78% | 368,000 -132,000 | -26% | -$14.3M |
|
6
Medtronic
MDT
$119B
| $39.6M | 2.76% | 335,000 +15,000 | +5% | +$1.77M |
|
7
Vertex Pharmaceuticals
VRTX
$100B
| $36.2M | 2.52% | 168,421 +53,421 | +46% | +$11.5M |
|
8
Teladoc Health
TDOC
$1.37B
| $34.5M | 2.41% | 190,000 +75,000 | +65% | +$13.6M |
|
9
Guardant Health
GH
$8.41B
| $34.3M | 2.39% | 225,000 +55,000 | +32% | +$8.4M |
|
10
Elevance Health
ELV
$71.8B
| $34.1M | 2.38% | 95,000 +15,000 | +19% | +$5.38M |
|
11
CVS Health
CVS
$92.8B
| $33.9M | 2.36% | 450,000 +30,000 | +7% | +$2.26M |
|
|
12
Abbott
ABT
$231B
| $33M | 2.3% | 275,000 +125,000 | +83% | +$15M |
|
13
Eli Lilly
LLY
$657B
| $31.8M | 2.21% | 170,000 -10,000 | -6% | -$1.87M |
|
14
Humana
HUM
$36.5B
| $28.9M | 2.02% | 69,000 +11,000 | +19% | +$4.61M |
|
15
Centene
CNC
$14.3B
| $26.8M | 1.87% | 420,000 +135,000 | +47% | +$8.63M |
|
16
Cigna
CI
$80.3B
| $26.6M | 1.85% | 110,000 -30,000 | -21% | -$7.25M |
|
17
Nektar Therapeutics
NKTR
$568M
| $26.1M | 1.82% | 1,307,196 -42,804 | -3% | -$856K |
|
18
Boston Scientific
BSX
$156B
| $25.9M | 1.81% | 670,000 +140,000 | +26% | +$5.41M |
|
|
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $25.7M | 1.79% | 150,000 +50,000 | +50% | +$8.57M |
|
|
ABMD
20
DELISTED
Abiomed Inc
ABMD
| $24.9M | 1.73% | 78,000 +15,000 | +24% | +$4.78M |
|
|
AXNX
21
DELISTED
Axonics, Inc. Common Stock
AXNX
| $24.6M | 1.71% | 410,000 -50,000 | -11% | -$2.99M |
|
22
NovoCure
NVCR
$1.38B
| $23.8M | 1.66% | 180,000 +60,000 | +50% | +$7.93M |
|
23
Exact Sciences
EXAS
$8.98B
| $23.1M | 1.61% | 175,000 +100,000 | +133% | +$13.2M |
|
24
Gilead Sciences
GILD
$140B
| $22.6M | 1.58% | 350,000 -35,000 | -9% | -$2.26M |
|
|
XLRN
25
DELISTED
Acceleron Pharma Inc.
XLRN
| $21.7M | 1.51% | 160,000 | – | – |
|